03/28/2019
Statistics You Need to Think About
Statistics show the number of P*s falling out of research after one trial is 54%. The pool of experienced P*s is shrinking by 3% per year. You may say this is due to inexperience, but the results of research done by Tufts and Duke show that the reasons are the same frustrations you deal with every day at your site.
Trial design is becoming more complicated: a Ph 3 protocol has had a 60% increase in the number of procedures required since 2000. Tufts stated "compared to 10 years ago, protocols have more endpoints, procedures, eligibility criteria, CRF pages, amendments". More work is being required by sponsors to the site, greater regulatory issues, and the ongoing issues of financial viability at the sites .
Top 4 needs:
1) Developing site research infrastructure and staff
2) Optimizing trial ex*****on/conduct
3) Improving site budget/contract negotiations
4) Additional trials to conduct
If I can help you with #1 (utilizing some outsourced services), I can handle #3 myself, and #4 - I can direct you to a great Business Development resource – that leaves you “free” to handle #2 yourself, which would really result in “optimizing” your trial ex*****on! Why would you not address these opportunities?
46% of investigators report being unsatisfied with finance issues:
• The complex reimbursement process for the costs of clinical trials.
• The high level of administrative overhead — paperwork, regulatory, and IT — associated with running clinical trials. This overhead usually exceeds the expectations and budget, resulting is inadequate resourcing, and thus being stuck with a bad deal.
• Study budgets are flat while procedures per subject are increasing. Sites have seen increases in paperwork, protocol complexity, challenges with patient recruitment, mgmt and performance metrics, patient screening and informed consent complexity, site staff GCP/IT training and compliance requirements. BUT, Site budgets, have not increased to address this added overhead.
• Not addressing any annual inflation adjustments, ignoring the fact a site’s expenses across the board are constantly increasing.
• Slow payment process: The studies show that it takes between 122 and 140 days from a patient visit for a site to receive payment (number of days depends on whether from a pharma company or a CRO), greatly affecting a site’s cash flow.
If I can help you with these issues, why would you not address this opportunity? Contact me for assistance!